Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of RAS(ON) inhibitors in combination with ivonescimab in adults with advanced or metastatic solid tumors with a RAS mutation.

Trial Details

NCT ID
NCT07397338
Phase
PHASE1 / PHASE2
Sponsor
Revolution Medicines, Inc.
Status
RECRUITING
Cancer Type
Non-Small Cell (NSCLC) Lung Cancer
Interventions
  • Daraxonrasib
  • Elironrasib
  • Zoldonrasib
  • Ivonescimab
  • Carboplatin/Cisplatin + Pemetrexed (Dose Expansion Only)
  • cetuximab (Cohort C2 Only)
Locations (sample)
  • Scottsdale, Arizona, United States|33.50921,-111.89903
  • Los Angeles, California, United States|34.05223,-118.24368
  • San Francisco, California, United States|37.77493,-122.41942
  • Norwich, Connecticut, United States|41.52426,-72.07591
  • Lexington, Kentucky, United States|37.98869,-84.47772

Key Eligibility Criteria

  • At least 18 years old and has provided informed consent.
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
  • Histologically confirmed, locally advanced or metastatic solid tumor malignancy with documented RAS mutation in KRAS, HRAS, or NRAS.
  • Received and progressed or been intolerant to prior standard therapy (Part 1 Dose Exploration).

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Non-Small Cell (NSCLC) Lung Cancer Trials on Trialify →